Product
Ad26.RSV.preF-based vaccine
2 clinical trials
4 indications
Indication
Respiratory Syncytial Virus PreventionIndication
InfluenzaIndication
Human PreventionIndication
Respiratory Syncytial VirusClinical trial
A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 YearsStatus: Completed, Estimated PCD: 2022-03-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and OlderStatus: Completed, Estimated PCD: 2022-04-20